News News Release Feb 1, 2024 Management Strategic Business Partnership between ROHTO MediLuxe Europe and EMA AESTHETICS Oct 26, 2023 Management ROHTO Pharmaceutical Co., Ltd. Investing to Develop Novel Solution for Urinary Incontinence Symptoms, Venturing into New Values, Products, and Businesses in the Healthcare Sector. May 12, 2023 Sustainability Establishment of Sustainability Targets 2030 (environmental and social axis) May 10, 2023 Management Fujita Gakuen and ROHTO Pharmaceutical Co., Ltd. established a joint venture and entered the real-world data business. Sep 30, 2022 R&D Announcement: Commencement of Phase II Clinical Trials for Janus Kinase Inhibitor "ROH-201" in Japan See Past News Relese News Release RSS IR News See Past IR News IR News RSS R&D Release Sep 30, 2022 Announcement: Commencement of Phase II Clinical Trials for Janus Kinase Inhibitor "ROH-201" in Japan Mar 28, 2022 Notice of Commencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202" Sep 7, 2021 Announcement of Collaborative Research Agreement for Creating a Solution to Predict Systemic Diseases from Eye Health Information Jul 20, 2021 Announcement of Commencement of Domestic Phase III Clinical Trial for Cytomegalovirus Endotheliitis Jun 30, 2021 We evaluated the performance of rapid test kits for coronavirus (SARS-CoV-2) antigens using laboratory samples. See Past R&D Release R&D News RSS We Connect to Create Future of Society We want to contribute to the future potential of society by supporting physical and mental health. SustainabilityImproving the future of society and the planet through health About UsDelivering values born from the thoughts of each individuals R&DLeveraging transcends fields knowledge for new products and services Investor RelationsTo continue contributingacross borders
